MODERN PHARMACEUTICAL TREATMENT OF PULMONARY ARTERIAL HYPERTENSION
The review is devoted to modern pharmaceutical treatment of pulmonary arterial hypertension (PAH). In 1970-80s, it was based on high-dose calcium antagonists, CAs (e.g., nifedipine 240 mg/d), which were effective only in some patients with primary (idiopathic) PAH. CAs were combined with digoxin, in...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
«FIRMA «SILICEA» LLC
2009-12-01
|
| Series: | Российский кардиологический журнал |
| Subjects: | |
| Online Access: | https://russjcardiol.elpub.ru/jour/article/view/1409 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849341478851051520 |
|---|---|
| author | D. V. Preobrazhensky B. A. Sidorenko S. A. Pataraya T. A. Batyraliev Z. A. Niyazova-Karben Mesut Ishlek |
| author_facet | D. V. Preobrazhensky B. A. Sidorenko S. A. Pataraya T. A. Batyraliev Z. A. Niyazova-Karben Mesut Ishlek |
| author_sort | D. V. Preobrazhensky |
| collection | DOAJ |
| description | The review is devoted to modern pharmaceutical treatment of pulmonary arterial hypertension (PAH). In 1970-80s, it was based on high-dose calcium antagonists, CAs (e.g., nifedipine 240 mg/d), which were effective only in some patients with primary (idiopathic) PAH. CAs were combined with digoxin, indirect anticoagulants and oxygen. In 1990s, PAH therapy included prostanoids, endothelin receptor (ER) blockers and phosphodiesterase (PDE) inhibitors, which are more selective pulmonary vasodilatators than CAs, and therefore are safer for long-term treatment. Prospective studies have demonstrated that continuous intravenous infusion of epoprostenol and ET receptor blocker bosentan treatment improve survival of PAH patients receiving traditional therapy. Clinical effectiveness of epoprostenol is similar to that of subcutaneously administered trepostinil, and bosentan is similar to PDE inhibitor Type 5 sildenafil. Bosentan increases the effectiveness of intravenous epoprostenol and inhaled trepostinil. |
| format | Article |
| id | doaj-art-be849ca8d18d45629d9bfb4c7d225b54 |
| institution | Kabale University |
| issn | 1560-4071 2618-7620 |
| language | Russian |
| publishDate | 2009-12-01 |
| publisher | «FIRMA «SILICEA» LLC |
| record_format | Article |
| series | Российский кардиологический журнал |
| spelling | doaj-art-be849ca8d18d45629d9bfb4c7d225b542025-08-20T03:43:37Zrus«FIRMA «SILICEA» LLCРоссийский кардиологический журнал1560-40712618-76202009-12-010669791197MODERN PHARMACEUTICAL TREATMENT OF PULMONARY ARTERIAL HYPERTENSIOND. V. Preobrazhensky0B. A. Sidorenko1S. A. Pataraya2T. A. Batyraliev3Z. A. Niyazova-Karben4Mesut Ishlek5Учебно-научный медицинский центр Управления делами Президента Российской Федерации, МоскваУчебно-научный медицинский центр Управления делами Президента Российской Федерации, МоскваУчебно-научный медицинский центр Управления делами Президента Российской Федерации, МоскваМедицинский центр имени Сани Конукоглы и Университет, Газиантеп, ТурцияМедицинский центр имени Сани Конукоглы и Университет, Газиантеп, ТурцияМедицинский центр имени Сани Конукоглы и Университет, Газиантеп, ТурцияThe review is devoted to modern pharmaceutical treatment of pulmonary arterial hypertension (PAH). In 1970-80s, it was based on high-dose calcium antagonists, CAs (e.g., nifedipine 240 mg/d), which were effective only in some patients with primary (idiopathic) PAH. CAs were combined with digoxin, indirect anticoagulants and oxygen. In 1990s, PAH therapy included prostanoids, endothelin receptor (ER) blockers and phosphodiesterase (PDE) inhibitors, which are more selective pulmonary vasodilatators than CAs, and therefore are safer for long-term treatment. Prospective studies have demonstrated that continuous intravenous infusion of epoprostenol and ET receptor blocker bosentan treatment improve survival of PAH patients receiving traditional therapy. Clinical effectiveness of epoprostenol is similar to that of subcutaneously administered trepostinil, and bosentan is similar to PDE inhibitor Type 5 sildenafil. Bosentan increases the effectiveness of intravenous epoprostenol and inhaled trepostinil.https://russjcardiol.elpub.ru/jour/article/view/1409calcium antagonistsprostanoidsepoprostenoltrepostinililoprostbosentansildenafil |
| spellingShingle | D. V. Preobrazhensky B. A. Sidorenko S. A. Pataraya T. A. Batyraliev Z. A. Niyazova-Karben Mesut Ishlek MODERN PHARMACEUTICAL TREATMENT OF PULMONARY ARTERIAL HYPERTENSION Российский кардиологический журнал calcium antagonists prostanoids epoprostenol trepostinil iloprost bosentan sildenafil |
| title | MODERN PHARMACEUTICAL TREATMENT OF PULMONARY ARTERIAL HYPERTENSION |
| title_full | MODERN PHARMACEUTICAL TREATMENT OF PULMONARY ARTERIAL HYPERTENSION |
| title_fullStr | MODERN PHARMACEUTICAL TREATMENT OF PULMONARY ARTERIAL HYPERTENSION |
| title_full_unstemmed | MODERN PHARMACEUTICAL TREATMENT OF PULMONARY ARTERIAL HYPERTENSION |
| title_short | MODERN PHARMACEUTICAL TREATMENT OF PULMONARY ARTERIAL HYPERTENSION |
| title_sort | modern pharmaceutical treatment of pulmonary arterial hypertension |
| topic | calcium antagonists prostanoids epoprostenol trepostinil iloprost bosentan sildenafil |
| url | https://russjcardiol.elpub.ru/jour/article/view/1409 |
| work_keys_str_mv | AT dvpreobrazhensky modernpharmaceuticaltreatmentofpulmonaryarterialhypertension AT basidorenko modernpharmaceuticaltreatmentofpulmonaryarterialhypertension AT sapataraya modernpharmaceuticaltreatmentofpulmonaryarterialhypertension AT tabatyraliev modernpharmaceuticaltreatmentofpulmonaryarterialhypertension AT zaniyazovakarben modernpharmaceuticaltreatmentofpulmonaryarterialhypertension AT mesutishlek modernpharmaceuticaltreatmentofpulmonaryarterialhypertension |